Clinical Trial Update: The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease [Phase 1]

View source ↗

Summary

iRegene Therapeutics is recruiting for a Phase 1 study of NouvNeu001 to assess safety, tolerability, and preliminary efficacy in early-onset Parkinson's disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• NouvNeu001

Snippet

Sponsor: iRegene Therapeutics Co., Ltd. | Conditions: Early-onset Parkinson's Disease | Phase 1 | Status: RECRUITING